Abstract
The Na+/H+-exchanger 1, NHE1 (SLC9A1) and the electroneutral Na+,HCO3 --cotransporter NBCn1 (SLC4A7) are coexpressed in a wide range of tissues. Under normal physiological conditions these transporters play an ostensibly similar role, namely that of net acid extrusion after cellular acidification. In addition, they have been implicated in multiple other cellular processes, including regulation of transepithelial transport, cell volume, cell death/survival balance, and cell motility. In spite of their apparent functional similarity, the two transporters also serve distinctly different functions and are differentially regulated. Here, we provide an update on the basic structure, function, regulation, physiology and pharmacology of NHE1 and NBCn1, with particular focus on the factors responsible for their functional similarities and differences. Finally, we highlight recent findings implicating these transporters in cancer development, and discuss issues relating to NHE1 and NBCn1 as potential targets in cancer treatment.
Keywords: SLC9A1, SLC4A7, cancer, acidification, bicarbonate, EIPA, cariporide, DIDS, S0859, Na+/H+-exchanger 1
Current Pharmaceutical Design
Title: Physiology, Pharmacology and Pathophysiology of the pH Regulatory Transport Proteins NHE1 and NBCn1: Similarities, Differences, and Implications for Cancer Therapy
Volume: 18 Issue: 10
Author(s): E. Boedtkjer, L. Bunch and S. F. Pedersen
Affiliation:
Keywords: SLC9A1, SLC4A7, cancer, acidification, bicarbonate, EIPA, cariporide, DIDS, S0859, Na+/H+-exchanger 1
Abstract: The Na+/H+-exchanger 1, NHE1 (SLC9A1) and the electroneutral Na+,HCO3 --cotransporter NBCn1 (SLC4A7) are coexpressed in a wide range of tissues. Under normal physiological conditions these transporters play an ostensibly similar role, namely that of net acid extrusion after cellular acidification. In addition, they have been implicated in multiple other cellular processes, including regulation of transepithelial transport, cell volume, cell death/survival balance, and cell motility. In spite of their apparent functional similarity, the two transporters also serve distinctly different functions and are differentially regulated. Here, we provide an update on the basic structure, function, regulation, physiology and pharmacology of NHE1 and NBCn1, with particular focus on the factors responsible for their functional similarities and differences. Finally, we highlight recent findings implicating these transporters in cancer development, and discuss issues relating to NHE1 and NBCn1 as potential targets in cancer treatment.
Export Options
About this article
Cite this article as:
Boedtkjer E., Bunch L. and F. Pedersen S., Physiology, Pharmacology and Pathophysiology of the pH Regulatory Transport Proteins NHE1 and NBCn1: Similarities, Differences, and Implications for Cancer Therapy, Current Pharmaceutical Design 2012; 18 (10) . https://dx.doi.org/10.2174/138161212799504830
DOI https://dx.doi.org/10.2174/138161212799504830 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Glycosylation Pathways as Drug Targets for Cancer: Glycosidase Inhibitors
Mini-Reviews in Medicinal Chemistry Matrix Metalloproteinases
Current Medicinal Chemistry Recent Nanocarrier Approaches for Targeted Drug Delivery in Cancer Therapy
Current Molecular Pharmacology Practical Aspects in the Use of Biomarkers for the Development of Cancer Vaccines
Current Cancer Therapy Reviews Base Excision Repair, the Redox Environment and Therapeutic Implications
Current Molecular Pharmacology New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPARγ Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy
Current Cancer Drug Targets The PI3 Kinase Signaling Pathway in Prostate Cancer
Current Cancer Drug Targets ABC Transporter Inhibitors in Reversing Multidrug Resistance to Chemotherapy
Current Drug Targets Evaluation of Osteoporosis Risk Associated with Chronic Use of Morphine, Fentanyl and Tramadol in Adult Female Rats
Current Drug Safety Improvement of Nonviral Gene Therapy by Epstein-Barr Virus (EBV)-based Plasmid Vectors
Current Gene Therapy E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers
Current Cancer Drug Targets Colloidal Drug Delivery Systems in Vaccine Delivery
Current Drug Targets Role of Cell Cycle Biomarkers in Human Papillomavirus Related Uterine Lesions
Current Pharmaceutical Design Challenges and Persistent Questions in the Treatment of Trichomoniasis
Current Topics in Medicinal Chemistry Peniciketal A, A Novel Spiroketal Compound, Exerts Anticancer Effects by Inhibiting Cell Proliferation, Migration and Invasion of A549 Lung Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Molecular Targeting of Lymphatics for Therapy
Current Pharmaceutical Design Viewing the Emphasis on State-of-the-Art Magnetic Nanoparticles: Synthesis, Physical Properties, and Applications in Cancer Theranostics
Current Pharmaceutical Design Bee Venom: Its Potential Use in Alternative Medicine
Anti-Infective Agents Recent Advances in Application of Poly-Epsilon-Caprolactone and its Derivative Copolymers for Controlled Release of Anti-Tumor Drugs
Current Cancer Drug Targets Animal Venoms have Potential to Treat Cancer
Current Topics in Medicinal Chemistry